抗抑郁药相关性性功能障碍妇女的西尔德纳菲尔治疗:一个随机对照试验
H George Nurnberg1, Paula L Hensley, Julia R Heiman
1Department of Psychiatry, University of New Mexico School of Medicine, 2400 Tucker NE, MC 09 5030, Albuquerque, NM 87131-0001, USA. gnurnberg@salud.unm.edu
JAMA
|July 24, 2008
概括
西尔德纳菲尔有效地改善了与抗抑郁药相关的女性性功能障碍,为这种常见的副作用提供了潜在的治疗方法. 这项研究为在服用血清素再吸收抑制剂 (SRIs) 时经历性功能障碍的女性提供了希望.
科学领域:
- 临床药理学 临床药理学
- 妇女健康 妇女健康
- 精神病学是一个精神病学.
背景情况:
- 抗抑郁药相关性性功能障碍 (ASSD) 是一个普遍的问题,经常导致治疗不遵守.
- 目前针对女性ASSD的治疗方法缺乏证明的疗效.
- 选择性和非选择性血清素再吸收抑制剂 (SRIs) 是常见的抗抑郁药.
研究的目的:
- 评估西尔德纳菲尔在治疗使用SRI的女性性功能障碍方面的疗效.
- 调查西尔代纳菲尔对女性性功能的各种措施的影响.
主要方法:
- 一项为期8周的随机,双盲,安慰剂对照试验,涉及98名绝经前妇女,在SRIs上经历性功能障碍,抑郁症缓解.
- 参与者在性活动之前接受了西尔代纳菲尔 (灵活剂量50-100毫克) 或安慰剂.
- 主要结局:临床全球印象性功能尺度的变化;次要结局包括经过验证的性功能问卷和性活动日志.
主要成果:
- 与安慰剂 (P = .001) 相比,西尔德纳菲尔治疗显示了主要结局指标 (临床全球印象性功能得分) 的统计学上显著改善.
- 二次结果测量也表明了西尔德纳菲尔的好处,尽管具体结果各不相同.
- 常见的副作用包括头痛,发红和消化不良;没有严重的不良事件导致戒断.
结论:
- 西尔德纳菲尔在服用血清素再吸收抑制剂的女性中减轻性功能障碍方面表现出有效性.
- 这些发现表明,西尔德纳菲尔是治疗女性抗抑郁药相关性性功能障碍的潜在治疗选择.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
